» Articles » PMID: 35462875

Sea Cucumber Compounds Targeting NF-κB in Cancer Treatment

Overview
Publisher Sage Publications
Specialty Biology
Date 2022 Apr 25
PMID 35462875
Authors
Affiliations
Soon will be listed here.
Abstract

Cancer is a major health problem worldwide and the leading cause of death in many countries. It remains challenging to find anticancer treatments that work efficiently for varying types of cancer cells. Several studies revealed that nuclear factor kappa B (NF-κB) is a family of dimeric transcription factors that induce tumor promotion, progression, and therapeutic resistance, providing evidence that NF-kB may be a promising target for cancer drugs. Some research has found that sea cucumber biocompounds have anticancer properties, but further research is essential to confirm anticancer targets. This manuscript discusses the mechanisms of anticancer targeting the NF-κB signaling pathway induced by sea cucumber-derived compounds. Additional database analysis showed the protein targeted by the compounds involved in several pathways related to the NF-κB network. Moreover, SwissADME predicted druglikeliness properties of the active compounds of sea cucumber. The discussion is expected to provide new insight into the promising potential of these marine natural products for the treatment of many different types of cancers.

Citing Articles

Toxicity Effect of Holothuria Lessoni Sea Cucumber on Cancerous Mitochondria Obtained from Rat Model of Hepatocellular Carcinoma.

Seydi E, Shahbazi N, Barzegar M, Nazemi M, Mohsenifar Z, Eskandari M Asian Pac J Cancer Prev. 2024; 25(10):3717-3723.

PMID: 39471040 PMC: 11711362. DOI: 10.31557/APJCP.2024.25.10.3717.


Targeting the NF-κB pathway as a potential regulator of immune checkpoints in cancer immunotherapy.

Ebrahimi N, Abdulwahid A, Mansouri A, Karimi N, Bostani R, Beiranvand S Cell Mol Life Sci. 2024; 81(1):106.

PMID: 38418707 PMC: 10902086. DOI: 10.1007/s00018-023-05098-8.


Sea cucumber-derived compounds for treatment of dyslipidemia: A review.

Lin P, Shen N, Yin F, Guo S Front Pharmacol. 2022; 13:1000315.

PMID: 36188620 PMC: 9515789. DOI: 10.3389/fphar.2022.1000315.

References
1.
Careaga V, Bueno C, Muniain C, Alche L, Maier M . Antiproliferative, cytotoxic and hemolytic activities of a triterpene glycoside from Psolus patagonicus and its desulfated analog. Chemotherapy. 2008; 55(1):60-8. DOI: 10.1159/000180340. View

2.
Feng Z, Cao J, Zhang Q, Lin L . The drug likeness analysis of anti-inflammatory clerodane diterpenoids. Chin Med. 2020; 15(1):126. PMC: 7727157. DOI: 10.1186/s13020-020-00407-w. View

3.
Xia Y, Shen S, Verma I . NF-κB, an active player in human cancers. Cancer Immunol Res. 2014; 2(9):823-30. PMC: 4155602. DOI: 10.1158/2326-6066.CIR-14-0112. View

4.
Chaturvedi M, Sung B, Yadav V, Kannappan R, Aggarwal B . NF-κB addiction and its role in cancer: 'one size does not fit all'. Oncogene. 2010; 30(14):1615-30. PMC: 3141287. DOI: 10.1038/onc.2010.566. View

5.
Verheij H . Leadlikeness and structural diversity of synthetic screening libraries. Mol Divers. 2006; 10(3):377-88. DOI: 10.1007/s11030-006-9040-6. View